| |
| |
|
| Insider
Information: |
Lepore Patrick G |
| Relationship: |
Director |
| City: |
Fair Lawn |
| State: |
NJ |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
6 |
|
| Direct
Shares |
1,081,895 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$1,360,869 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
1,081,895 |
|
|
| Total
Value |
$1,360,869 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
10
|
0
|
|
Stock
price went up :
|
3
|
0
|
| Stock
price went down : |
7
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
 -39.4%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Par Pharmaceutical Companies Inc |
PRX |
Executive Chairman, Di... |
2012-09-28 |
0 |
2012-09-28 |
0 |
Premium* |
|
|
PharMerica Corporation |
PMC |
Director |
2017-12-07 |
0 |
2013-01-14 |
0 |
Premium* |
|
|
Innoviva Inc |
INVA |
Director |
2017-04-20 |
58,278 |
2016-10-26 |
0 |
Premium* |
|
|
Lannett Co Inc |
LCI |
Director |
2022-11-10 |
587,145 |
2018-05-11 |
0 |
Premium* |
|
|
Matinas Biopharma Holdings, Inc. |
MTNB |
Director |
2020-05-14 |
400,000 |
2019-05-16 |
0 |
Premium* |
|
|
VYNE Therapeutics Inc |
VYNE |
Director |
2023-11-15 |
36,472 |
2020-12-03 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
73 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 2 of 3
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| PRX |
Par Pharmaceutical Compan... |
Chairman, CEO and President |
• • – |
2010-08-09 |
4 |
D |
$28.51 |
$190,732 |
D/D |
(6,690) |
226,420 |
0 |
- |
|
| PRX |
Par Pharmaceutical Compan... |
Chairman, Pres, CEO |
• – – |
2011-01-10 |
4/A |
D |
$36.00 |
$251,352 |
D/D |
(6,982) |
265,817 |
0 |
- |
|
| PRX |
Par Pharmaceutical Compan... |
Chairman, President & CEO |
• • – |
2011-09-06 |
4 |
B |
$25.92 |
$207,360 |
I/I |
8,000 |
23,000 |
2.66 |
- |
|
| PRX |
Par Pharmaceutical Compan... |
Chairman, President & CEO |
• • – |
2011-08-09 |
4 |
D |
$29.09 |
$252,792 |
D/D |
(8,690) |
254,880 |
0 |
- |
|
| VYNE |
VYNE Therapeutics Inc |
Director |
– • – |
2021-03-15 |
4 |
B |
$7.41 |
$92,563 |
D/D |
12,500 |
25,000 |
2.39 |
% |
|
| VYNE |
VYNE Therapeutics Inc |
Director |
– • – |
2021-05-26 |
4 |
B |
$3.60 |
$44,958 |
D/D |
12,500 |
37,500 |
2.39 |
% |
|
| VYNE |
VYNE Therapeutics Inc |
Director |
– • – |
2021-08-25 |
4 |
B |
$1.60 |
$20,000 |
D/D |
12,500 |
50,000 |
2.39 |
% |
|
| VYNE |
VYNE Therapeutics Inc |
Director |
– • – |
2023-11-15 |
4 |
B |
$3.91 |
$50,778 |
D/D |
13,000 |
36,472 |
2.39 |
- |
|
| LCI |
Lannett Co Inc |
Director |
– • – |
2018-07-20 |
4 |
A |
$0.00 |
$0 |
D/D |
16,195 |
42,895 |
0 |
- |
|
| INVA |
Innoviva Inc |
Director |
– • – |
2017-04-20 |
4 |
A |
$0.00 |
$0 |
D/D |
19,857 |
58,278 |
0 |
- |
|
| LCI |
Lannett Co Inc |
Director |
– • – |
2021-05-11 |
4 |
B |
$4.18 |
$83,600 |
D/D |
20,000 |
260,326 |
2.39 |
% |
|
| LCI |
Lannett Co Inc |
Director |
– • – |
2021-09-08 |
4 |
B |
$3.31 |
$66,200 |
D/D |
20,000 |
337,145 |
2.39 |
% |
|
| VYNE |
VYNE Therapeutics Inc |
Director |
– • – |
2023-03-20 |
4 |
B |
$2.48 |
$49,680 |
D/D |
20,000 |
23,472 |
2.39 |
- |
|
| PRX |
Par Pharmaceutical Compan... |
Chief Executive Officer & Pres |
• • – |
2007-03-22 |
4 |
A |
$0.00 |
$0 |
D/D |
22,600 |
57,600 |
0 |
- |
|
| LCI |
Lannett Co Inc |
Director |
– • – |
2018-05-11 |
4 |
B |
$15.13 |
$378,250 |
D/D |
25,000 |
26,700 |
2.39 |
- |
|
| LCI |
Lannett Co Inc |
Director |
– • – |
2018-08-31 |
4 |
B |
$5.34 |
$133,500 |
D/D |
25,000 |
67,895 |
2.39 |
- |
|
| LCI |
Lannett Co Inc |
Director |
– • – |
2018-12-13 |
4 |
B |
$5.10 |
$127,500 |
D/D |
25,000 |
92,895 |
2.39 |
- |
|
| LCI |
Lannett Co Inc |
Director |
– • – |
2019-02-12 |
4 |
B |
$8.93 |
$223,250 |
D/D |
25,000 |
117,895 |
2.39 |
- |
|
| LCI |
Lannett Co Inc |
Director |
– • – |
2019-05-08 |
4 |
B |
$7.32 |
$183,000 |
D/D |
25,000 |
142,895 |
2.39 |
- |
|
| LCI |
Lannett Co Inc |
Director |
– • – |
2019-09-03 |
4 |
B |
$9.82 |
$245,500 |
D/D |
25,000 |
201,340 |
2.39 |
- |
|
| PRX |
Par Pharmaceutical Compan... |
Chairman, Pres and CEO |
• • – |
2011-01-11 |
4 |
D |
$35.98 |
$964,120 |
D/D |
(26,796) |
264,270 |
0 |
- |
|
| PRX |
Par Pharmaceutical Compan... |
Chairman, Pres and CEO |
• • – |
2011-01-11 |
4 |
A |
$0.00 |
$0 |
D/D |
27,004 |
291,066 |
0 |
- |
|
| PRX |
Par Pharmaceutical Compan... |
Chairman, President & CEO |
• • – |
2010-01-04 |
4 |
A |
$0.00 |
$0 |
D/D |
27,066 |
240,402 |
0 |
- |
|
| PMC |
PharMerica Corporation |
Director |
– • – |
2017-12-07 |
4 |
D |
$29.25 |
$864,923 |
D/D |
(29,570) |
0 |
0 |
- |
|
| PRX |
Par Pharmaceutical Compan... |
Chairman, CEO and President |
• • – |
2007-10-03 |
4 |
B |
$18.36 |
$550,800 |
I/I |
30,000 |
15,000 |
2.66 |
- |
|
73 Records found
|
|
Page 2 of 3 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
